Global Health News: AstraZeneca's US Deal and India's Cough Syrup Scandal

This news brief highlights AstraZeneca's successful medicine deal in the US, enhancing drug affordability and protection from tariffs. It also covers an investigation into Sresan Pharma in India, linked to child deaths due to toxic cough syrup, showcasing global health challenges.

AstraZeneca has struck a significant deal in the United States, as CEO Pascal Soriot stood beside President Donald Trump in the Oval Office to announce a medicine agreement aimed at reducing drug costs for millions. The agreement marks a milestone for the company, becoming the first non-U.S. drugmaker to avoid steep tariffs on imports into the world's largest pharmaceutical market.

In India, authorities are pursuing an investigation into Sresan Pharma, a cough syrup manufacturer connected to several child fatalities. The company's products were found to contain diethylene glycol, a toxic chemical at dangerously high levels. At least 19 children have died following consumption of the syrup, leading to a ban on the product and a continuing probe by the financial crime agency.

These stories underscore the intricate dynamics of the global health sector, from pharmaceutical negotiations at the highest levels to tragic lapses in drug safety within local markets.

(With inputs from agencies.)